165 related articles for article (PubMed ID: 34107378)
1. High expression of SCHLAP1 in primary prostate cancer is an independent predictor of biochemical recurrence, despite substantial heterogeneity.
Kidd SG; Carm KT; Bogaard M; Olsen LG; Bakken AC; Løvf M; Lothe RA; Axcrona K; Axcrona U; Skotheim RI
Neoplasia; 2021 Jun; 23(6):634-641. PubMed ID: 34107378
[TBL] [Abstract][Full Text] [Related]
2. RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1.
Prensner JR; Zhao S; Erho N; Schipper M; Iyer MK; Dhanasekaran SM; Magi-Galluzzi C; Mehra R; Sahu A; Siddiqui J; Davicioni E; Den RB; Dicker AP; Karnes RJ; Wei JT; Klein EA; Jenkins RB; Chinnaiyan AM; Feng FY
Lancet Oncol; 2014 Dec; 15(13):1469-1480. PubMed ID: 25456366
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer.
Mehra R; Udager AM; Ahearn TU; Cao X; Feng FY; Loda M; Petimar JS; Kantoff P; Mucci LA; Chinnaiyan AM
Eur Urol; 2016 Oct; 70(4):549-552. PubMed ID: 26724257
[TBL] [Abstract][Full Text] [Related]
4. A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies.
Chua MLK; Lo W; Pintilie M; Murgic J; Lalonde E; Bhandari V; Mahamud O; Gopalan A; Kweldam CF; van Leenders GJLH; Verhoef EI; Hoogland AM; Livingstone J; Berlin A; Dal Pra A; Meng A; Zhang J; Orain M; Picard V; Hovington H; Bergeron A; Lacombe L; Fradet Y; Têtu B; Reuter VE; Fleshner N; Fraser M; Boutros PC; van der Kwast TH; Bristow RG
Eur Urol; 2017 Nov; 72(5):665-674. PubMed ID: 28511883
[TBL] [Abstract][Full Text] [Related]
5. A novel RNA in situ hybridization assay for the long noncoding RNA SChLAP1 predicts poor clinical outcome after radical prostatectomy in clinically localized prostate cancer.
Mehra R; Shi Y; Udager AM; Prensner JR; Sahu A; Iyer MK; Siddiqui J; Cao X; Wei J; Jiang H; Feng FY; Chinnaiyan AM
Neoplasia; 2014 Dec; 16(12):1121-7. PubMed ID: 25499224
[TBL] [Abstract][Full Text] [Related]
6. GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture.
Jeyapala R; Savio AJ; Olkhov-Mitsel E; Kamdar S; Zhao F; Cuizon C; Liu RSC; Zlotta A; Fleshner N; van der Kwast T; Bapat B
Eur Urol Oncol; 2019 May; 2(3):231-238. PubMed ID: 31200836
[TBL] [Abstract][Full Text] [Related]
7. Large cribriform growth pattern identifies ISUP grade 2 prostate cancer at high risk for recurrence and metastasis.
Hollemans E; Verhoef EI; Bangma CH; Rietbergen J; Helleman J; Roobol MJ; van Leenders GJLH
Mod Pathol; 2019 Jan; 32(1):139-146. PubMed ID: 30349027
[TBL] [Abstract][Full Text] [Related]
8. Long non‑coding RNA SChLAP1 regulates the proliferation of triple negative breast cancer cells via the miR‑524‑5p/HMGA2 axis.
Bai X; Zhang S; Qiao J; Xing X; Li W; Zhang H; Xie J
Mol Med Rep; 2021 Jun; 23(6):. PubMed ID: 33846810
[TBL] [Abstract][Full Text] [Related]
9. A potential panel of four-long noncoding RNA signature in prostate cancer predicts biochemical recurrence-free survival and disease-free survival.
Huang TB; Dong CP; Zhou GC; Lu SM; Luan Y; Gu X; Liu L; Ding XF
Int Urol Nephrol; 2017 May; 49(5):825-835. PubMed ID: 28188414
[TBL] [Abstract][Full Text] [Related]
10. Long Noncoding RNA SChLAP1 Accelerates the Proliferation and Metastasis of Prostate Cancer via Targeting miR-198 and Promoting the MAPK1 Pathway.
Li Y; Luo H; Xiao N; Duan J; Wang Z; Wang S
Oncol Res; 2018 Jan; 26(1):131-143. PubMed ID: 28492138
[TBL] [Abstract][Full Text] [Related]
11. Long Noncoding RNA
Ji J; Xu R; Ding K; Bao G; Zhang X; Huang B; Wang X; Martinez A; Wang X; Li G; Miletic H; Thorsen F; Bjerkvig R; Xiang L; Han B; Chen A; Li X; Wang J
Clin Cancer Res; 2019 Nov; 25(22):6868-6881. PubMed ID: 31492748
[TBL] [Abstract][Full Text] [Related]
12. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.
Klein EA; Cooperberg MR; Magi-Galluzzi C; Simko JP; Falzarano SM; Maddala T; Chan JM; Li J; Cowan JE; Tsiatis AC; Cherbavaz DB; Pelham RJ; Tenggara-Hunter I; Baehner FL; Knezevic D; Febbo PG; Shak S; Kattan MW; Lee M; Carroll PR
Eur Urol; 2014 Sep; 66(3):550-60. PubMed ID: 24836057
[TBL] [Abstract][Full Text] [Related]
13. The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex.
Prensner JR; Iyer MK; Sahu A; Asangani IA; Cao Q; Patel L; Vergara IA; Davicioni E; Erho N; Ghadessi M; Jenkins RB; Triche TJ; Malik R; Bedenis R; McGregor N; Ma T; Chen W; Han S; Jing X; Cao X; Wang X; Chandler B; Yan W; Siddiqui J; Kunju LP; Dhanasekaran SM; Pienta KJ; Feng FY; Chinnaiyan AM
Nat Genet; 2013 Nov; 45(11):1392-8. PubMed ID: 24076601
[TBL] [Abstract][Full Text] [Related]
14. Identification of seven long noncoding RNAs signature for prediction of biochemical recurrence in prostate cancer.
Shao N; Zhu Y; Wan FN; Ye DW
Asian J Androl; 2019; 21(6):618-622. PubMed ID: 30860081
[TBL] [Abstract][Full Text] [Related]
15. Molecular Lymph Node Status for Prognostic Stratification of Prostate Cancer Patients Undergoing Radical Prostatectomy with Extended Pelvic Lymph Node Dissection.
Heck MM; Retz M; Bandur M; Souchay M; Vitzthum E; Weirich G; Schuster T; Autenrieth M; Kübler H; Maurer T; Thalgott M; Herkommer K; Gschwend JE; Nawroth R
Clin Cancer Res; 2018 May; 24(10):2342-2349. PubMed ID: 29463560
[No Abstract] [Full Text] [Related]
16. Negative LC3b immunoreactivity in cancer cells is an independent prognostic predictor of prostate cancer specific death.
Mortezavi A; Salemi S; Rupp NJ; Rüschoff JH; Hermanns T; Poyet C; Randazzo M; Simon HU; Moch H; Sulser T; Wild P; Eberli D
Oncotarget; 2017 May; 8(19):31765-31774. PubMed ID: 28423666
[TBL] [Abstract][Full Text] [Related]
17. Identification and Validation of PCAT14 as Prognostic Biomarker in Prostate Cancer.
Shukla S; Zhang X; Niknafs YS; Xiao L; Mehra R; Cieślik M; Ross A; Schaeffer E; Malik B; Guo S; Freier SM; Bui HH; Siddiqui J; Jing X; Cao X; Dhanasekaran SM; Feng FY; Chinnaiyan AM; Malik R
Neoplasia; 2016 Aug; 18(8):489-99. PubMed ID: 27566105
[TBL] [Abstract][Full Text] [Related]
18. Asporin is a stromally expressed marker associated with prostate cancer progression.
Rochette A; Boufaied N; Scarlata E; Hamel L; Brimo F; Whitaker HC; Ramos-Montoya A; Neal DE; Dragomir A; Aprikian A; Chevalier S; Thomson AA
Br J Cancer; 2017 Mar; 116(6):775-784. PubMed ID: 28152543
[TBL] [Abstract][Full Text] [Related]
19. Presence of invasive cribriform or intraductal growth at biopsy outperforms percentage grade 4 in predicting outcome of Gleason score 3+4=7 prostate cancer.
Kweldam CF; Kümmerlin IP; Nieboer D; Steyerberg EW; Bangma CH; Incrocci L; van der Kwast TH; Roobol MJ; van Leenders GJ
Mod Pathol; 2017 Aug; 30(8):1126-1132. PubMed ID: 28530220
[TBL] [Abstract][Full Text] [Related]
20. High nuclear karyopherin α 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy.
Grupp K; Habermann M; Sirma H; Simon R; Steurer S; Hube-Magg C; Prien K; Burkhardt L; Jedrzejewska K; Salomon G; Heinzer H; Wilczak W; Kluth M; Izbicki JR; Sauter G; Minner S; Schlomm T; Tsourlakis MC
Mod Pathol; 2014 Jan; 27(1):96-106. PubMed ID: 23887301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
